{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T02:12:13Z","timestamp":1773195133099,"version":"3.50.1"},"reference-count":21,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T00:00:00Z","timestamp":1773100800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To investigate the effect of delayed treatment on six-month visual outcomes in patients with type 2 diabetes mellitus (T2DM) complicated by branch retinal vein occlusion-associated macular edema (BRVO-ME).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This single-center retrospective cohort study included 148 patients diagnosed with BRVO-ME and receiving their first intravitreal ranibizumab injection between January 2024 and May 2025. Patients were stratified according to the interval from diagnosis to initial anti-vascular endothelial growth factor (VEGF) injection into early treatment (\u22647 days, n = 67), intermediate treatment (8\u201314 days, n = 52), and delayed treatment (&amp;gt;14 days, n = 29) groups. Baseline demographic, systemic, and ophthalmic parameters were collected. Best-corrected visual acuity (BCVA) and central macular thickness (CMT) (\u03bcm) were recorded at 1, 3, and 6 months post-injection. Multivariable linear regression was used to identify independent factors affecting six-month BCVA improvement.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      All groups exhibited BCVA improvement and CMT reduction at six months, with the early treatment group showing the greatest improvement. Multivariable regression identified delayed treatment as the only independent factor associated with six-month BCVA improvement (\u03b2 = \u22120.008, 95%\n                      <jats:italic>CI<\/jats:italic>\n                      : \u22120.014 to \u22120.002,\n                      <jats:italic>P<\/jats:italic>\n                      = 0.010). ROC analysis showed an AUC of 0.823 (95%\n                      <jats:italic>CI<\/jats:italic>\n                      : 0.751\u20130.884,\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt; 0.001) for delayed treatment predicting insufficient six-month visual improvement, with a sensitivity of 89.4% and specificity of 61.4% using a 14-day cutoff.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Initiation of anti-VEGF therapy within seven days of diagnosis is associated with greater six-month visual improvement in patients with BRVO-ME and T2DM. Delayed treatment may contribute to suboptimal visual recovery.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2026.1710295","type":"journal-article","created":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T05:31:17Z","timestamp":1773120677000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Delayed anti\u2013vascular endothelial growth factor therapy in patients with type 2 diabetes mellitus and branch retinal vein occlusion\u2013associated macular edema negatively affects visual outcomes"],"prefix":"10.3389","volume":"17","author":[{"given":"Yue","family":"Deng","sequence":"first","affiliation":[{"name":"Ophthalmology Center, Xinjiang 474 Hospital","place":["Urumqi, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanyu","family":"Liu","sequence":"additional","affiliation":[{"name":"Ophthalmology Center, Xinjiang 474 Hospital","place":["Urumqi, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xia","family":"Li","sequence":"additional","affiliation":[{"name":"Ophthalmology Center, Xinjiang 474 Hospital","place":["Urumqi, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liting","family":"Song","sequence":"additional","affiliation":[{"name":"Ophthalmology Center, Xinjiang 474 Hospital","place":["Urumqi, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoling","family":"Zhang","sequence":"additional","affiliation":[{"name":"Ophthalmology Center, Xinjiang 474 Hospital","place":["Urumqi, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1097\/apo.0000000000000598","article-title":"Update on retinal vein occlusion","volume":"12","author":"Romano","year":"2023","journal-title":"Asia Pac J Ophthalmol (Phila)"},{"key":"B2","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.survophthal.2020.02.004","article-title":"Cystoid macular edema related to cataract surgery and topical prostaglandin analogs: Mechanism, diagnosis, and management","volume":"65","author":"Holl\u00f3","year":"2020","journal-title":"Surv Ophthalmol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1146185","article-title":"Mendelian randomization indicates a causal contribution of type 2 diabetes to retinal vein occlusion","volume":"14","author":"Huang","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics14171983","article-title":"Integrated assessment of OCT, multimodal imaging, and cytokine markers for predicting treatment responses in retinal vein occlusion associated macular edema: A comparative review of anti-VEGF and steroid therapies","volume":"14","author":"Munk","year":"2024","journal-title":"Diagnostics (Basel)"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2024.176691","article-title":"The protective effect of anti-VEGF-A\/Ang-2 bispecific antibody on retinal vein occlusion model mice","volume":"976","author":"Kuriyama","year":"2024","journal-title":"Eur J Pharmacol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1159\/000541662","article-title":"Efficacy and safety of intravitreal faricimab in neovascular age-related macular degeneration, diabetic macular edema, and retinal vein occlusion: A meta-analysis","volume":"247","author":"Nichani","year":"2024","journal-title":"Ophthalmologica"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-021-05455-y","article-title":"Classification of good visual acuity over time in patients with branch retinal vein occlusion with macular edema using support vector machine","volume":"260","author":"Matsui","year":"2022","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1007\/s10792-024-03272-w","article-title":"Association between time to treatment and outcome in branch retinal vein occlusion","volume":"44","author":"Kitano","year":"2024","journal-title":"Int Ophthalmol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-021-05549-7","article-title":"The detrimental effects of delayed intravitreal anti-VEGF therapy for treating retinal pathology: lessons from a forced test-case","volume":"260","author":"Navarrete","year":"2022","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2024.1416668","article-title":"Cell and molecular targeted therapies for diabetic retinopathy","volume":"15","author":"Reddy","year":"2024","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0247161","article-title":"Short term visual and structural outcomes of anti-vascular endothelial growth factor (anti-VEGF) treatment delay during the first COVID-19 wave: A pilot study","volume":"16","author":"Naravane","year":"2021","journal-title":"PLoS One"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.2337\/dc25-S002","article-title":"2. Diagnosis and classification of diabetes: standards of care in diabetes\u20142025","volume":"48","year":"2024","journal-title":"Diabetes Care"},{"key":"B13","doi-asserted-by":"publisher","first-page":"P288","DOI":"10.1016\/j.ophtha.2019.09.029","article-title":"Retinal vein occlusions preferred practice pattern\u00ae","volume":"127","author":"Flaxel","year":"2020","journal-title":"Ophthalmology"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2024.01.029","article-title":"Efficacy and safety of faricimab for macular edema due to retinal vein occlusion: 24-week results from the BALATON and COMINO trials","volume":"131","author":"Tadayoni","year":"2024","journal-title":"Ophthalmology"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.oret.2022.06.016","article-title":"Anatomic biomarkers of macular edema associated with retinal vein occlusion","volume":"6","author":"Ciulla","year":"2022","journal-title":"Ophthalmol Retina"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1128811","article-title":"Mechanisms of macular edema","volume":"10","author":"Haydinger","year":"2023","journal-title":"Front Med (Lausanne)"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2021.1830969","article-title":"Ranibizumab for myopic choroidal neovascularization","volume":"20","author":"Ng","year":"2020","journal-title":"Expert Opin Biol Ther"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1016\/j.ophtha.2010.02.022","article-title":"Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study","volume":"117","author":"Brown","year":"2010","journal-title":"Ophthalmology"},{"key":"B19","doi-asserted-by":"publisher","first-page":"3301","DOI":"10.1038\/s41598-019-38934-8","article-title":"Anti-VEGF injection frequency correlates with visual acuity outcomes in pro re nata neovascular AMD treatment","volume":"9","author":"Wecker","year":"2019","journal-title":"Sci Rep"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2008.10.017","article-title":"SCORE Study report 1: baseline associations between central retinal thickness and visual acuity in patients with retinal vein occlusion","volume":"116","author":"Scott","year":"2009","journal-title":"Ophthalmology"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.survophthal.2022.08.002","article-title":"Delayed anti-VEGF injections during the COVID-19 pandemic and changes in visual acuity in patients with three common retinal diseases: A systematic review and meta-analysis","volume":"67","author":"Im","year":"2022","journal-title":"Surv Ophthalmol"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1710295\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T05:31:18Z","timestamp":1773120678000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1710295\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,10]]},"references-count":21,"alternative-id":["10.3389\/fendo.2026.1710295"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1710295","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,10]]},"article-number":"1710295"}}